← Leaderboards
Clotilde Lagier-Tourenne
University Of California, San Diego
$11,959,245
Attributed
$26,341,304
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,341,304 · 10
By mechanism
R01$12,605,259 · 5
RM1$5,093,143 · 1
RF1$4,592,673 · 2
R37$3,072,075 · 1
P50$978,154 · 1
Top collaborators
- Don W. Cleveland9 shared
- Daryl A Bosco6 shared
- Martin Marsala5 shared
- Paul Clark Blainey3 shared
- Cathleen M Lutz3 shared
- Michael Emmerson Ward3 shared
- David Cristopher Bragg2 shared
- Michael E Talkowski2 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Bogdan Bintu$5,562,976
- Jill C Wildonger$4,562,559
- Veronica Shubayev$5,703,515
- Steven L. Gonias$17,442,163
- Quyen Nguyen$5,238,357
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsAmyotrophic Lateral SclerosisGenesInduced Pluripotent Stem CellProteinsNeurodegenerative DisordersMotor NeuronsC9orf72Nerve DegenerationRna SplicingAffectMediatingNuclearLoss Of FunctionGeneticTranscriptAntisense OligonucleotidesMutationPathogenesisFrontotemporal DementiaTissuesLinkCollaborationsPhenotype
Grant awards (32)
Mechanism of stathmin-2-dependent axon maintenance, regeneration, and function$3,072,075
R37 · FY2025 · NS
Targeting Dysregulated RNA Splicing in Neurodegenerative Diseases$1,621,934
RM1 · FY2025 · NS · contact PI
In vivo modelling and therapy development for stathmin-2 loss in TDP-43 proteinopathies$824,437
R01 · FY2025 · NS · contact PI
Assembling the Genetic Architecture of X-linked Dystonia Parkinsonism$596,032
R01 · FY2025 · NS
Targeting Dysregulated RNA Splicing in Neurodegenerative Diseases$1,398,275
RM1 · FY2024 · NS · contact PI
Determining stathmin-2 function and potential as a therapeutic target in ALS/FTD$839,174
R01 · FY2024 · NS
In vivo modelling and therapy development for stathmin-2 loss in TDP-43 proteinopathies$824,437
R01 · FY2024 · NS · contact PI
Assembling the Genetic Architecture of X-linked Dystonia Parkinsonism$663,716
R01 · FY2024 · NS
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia$2,085,362
RF1 · FY2023 · NS
Targeting Dysregulated RNA Splicing in Neurodegenerative Diseases$2,072,934
RM1 · FY2023 · NS · contact PI
Determining stathmin-2 function and potential as a therapeutic target in ALS/FTD$853,797
R01 · FY2023 · NS
Disruption of Nucleocytoplasmic Transport in FUS-related Neurodegenerative Diseases$776,944
R01 · FY2023 · NS
Determining stathmin-2 function and potential as a therapeutic target in ALS/FTD$797,269
R01 · FY2022 · NS
Disruption of Nucleocytoplasmic Transport in FUS-related Neurodegenerative Diseases$790,424
R01 · FY2022 · NS
In vivo modelling and therapy development for stathmin-2 loss in TDP-43 proteinopathies$2,507,311
RF1 · FY2021 · NS · contact PI
Disruption of nucleocytoplasmic transport in FUS-related neurodegenerative diseases$806,490
R01 · FY2021 · NS
Determining stathmin-2 function and potential as a therapeutic target in ALS/FTD$798,489
R01 · FY2021 · NS
Disruption of nucleocytoplasmic transport in FUS-related neurodegenerative diseases$86,783
R01 · FY2021 · NS
Determining stathmin-2 function and potential as a therapeutic target in ALS/FTD$826,652
R01 · FY2020 · NS
Disruption of nucleocytoplasmic transport in FUS-related neurodegenerative diseases$814,945
R01 · FY2020 · NS
Disruption of nucleocytoplasmic transport in FUS-related neurodegenerative diseases$831,820
R01 · FY2019 · NS
Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansions$304,500
R01 · FY2018 · NS · contact PI
Project 2: Disease Mechanisms in Frontotemporal Dementia Linked to C9orf72 Expans$202,379
P50 · FY2018 · AG · contact PI
Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansions$304,500
R01 · FY2017 · NS · contact PI
Project 2: Disease Mechanisms in Frontotemporal Dementia Linked to C9orf72 Expans$202,450
P50 · FY2017 · AG · contact PI
Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansions$304,500
R01 · FY2016 · NS · contact PI
Project 2: Disease Mechanisms in Frontotemporal Dementia Linked to C9orf72 Expans$193,123
P50 · FY2016 · AG · contact PI
Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansions$245,226
R01 · FY2015 · NS · contact PI
Project 2: Disease Mechanisms in Frontotemporal Dementia Linked to C9orf72 Expans$180,577
P50 · FY2015 · AG · contact PI
Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansions$34,949
R01 · FY2015 · NS · contact PI
Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansions$280,175
R01 · FY2014 · NS · contact PI
Project 2: Disease Mechanisms in Frontotemporal Dementia Linked to C9orf72 Expans$199,625
P50 · FY2014 · AG · contact PI